Finance

Lists
Outlook: 61.9% bullish·14.3% bearish
Go to analysis
SYRE:NASDAQ
Spyre Therapeutics Inc
၇၉.၅၃ US$
-၁.၆၃%
(-၁.၃၂) 1D
အောက် ၈, GMT-၄ ၁၃:၂၅:၀၄  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for SYRE...
Open
၇၉.၅၈ US$
High
၈၀.၉၁ US$
Low
၇၇.၀၅ US$
Mkt. cap
၆၉၉.၂၂ ဋေ
Avg. vol.
၁.၄၉ သန်း
Volume
၁.၀၅ သန်း
52-wk high
၁၁၀.၁၈ US$
52-wk low
၁၇.၆၅ US$
EPS
-၂.၃၂ US$
Beta
၃.၁၀
Shares outstanding
၈.၈၂ ကုဋေ
No. of employees
၁၂၅
Open
၇၉.၅၈ US$
High
၈၀.၉၁ US$
Low
၇၇.၀၅ US$
Mkt. cap
၆၉၉.၂၂ ဋေ
Avg. vol.
၁.၄၉ သန်း
Volume
၁.၀၅ သန်း
52-wk high
၁၁၀.၁၈ US$
52-wk low
၁၇.၆၅ US$
EPS
-၂.၃၂ US$
Beta
၃.၁၀
Shares outstanding
၈.၈၂ ကုဋေ
No. of employees
၁၂၅
News stories
From web sources and news partners
Simply Wall Street
Simply Wall Street
·
ပြီးခဲ့သည့် ၁၄ နာရီ
Is Spyre Therapeutics (SYRE) Fully Priced Following Its $350 Million Equity Raise?
TipRanks
TipRanks
·
ပြီးခဲ့သည့် ၁ ရက်
Spyre Therapeutics Announces Major Equity Financing Agreement
TradingView
TradingView
·
ပြီးခဲ့သည့် ၁ ရက်
Spyre Therapeutics Launches $350 Million Stock Offering Underwritten by Jefferies, TD, Leerink, Stifel
Yahoo Finance
Yahoo Finance
·
ပြီးခဲ့သည့် ၁ ရက်
Spyre Therapeutics Sinks 14% on Upsized $350 Million Stock Offering Priced Below Market
About Spyre Therapeutics Inc
CEO-
Employees၁၂၅
Founded၂၀၁၃ ဇန် ၁
HeadquartersWaltham, မက်ဆာချူးဆက်ပြည်နယ်, ယူနိုက်တက်စတိတ်
Sector-
Websitespyre.com
Analyst ratings
Based on 13 analysts giving stock ratings to SYRE in the past 3 months
Strong buy
Buy
12
Hold
1
Sell
0
12-month forecast
Based on 13 Wall Street analysts offering 12 month price targets for SYRE in the last 3 months.
Highest
Current ၇၉.၅၃ US$
၁၃၀.၀၀ US$ (+၆၃.၄၆%)
Average
၁၂၂.၄၂ US$ (+၅၃.၉၃%)
Lowest
၁၁၀.၀၀ US$ (+၃၈.၃၁%)
Analyst
Recommendation
Action
Price target
Projected
Date
Yanan Zhu
Wells Fargo
Buy
Maintained
၁၁၅.၀၀ US$
+၄၄.၆%
10/02/2026
Debanjana Chatterjee
JonesTrading
Buy
Reiterated
၁၃၀.၀၀ US$
+၆၃.၅%
10/01/2026
Priyanka Grover
J.P. Morgan
Buy
Initiated
၁၁၀.၀၀ US$
+၃၈.၃%
10/01/2026
Hardik Parikh
J.P. Morgan
Buy
Initiated
၁၁၀.၀၀ US$
+၃၈.၃%
10/01/2026
David Nierengarten
Wedbush
Buy
Maintained
၁၂၃.၀၀ US$
+၅၄.၇%
09/09/2026
Akash Tewari
Jefferies
Buy
Maintained
၁၂၆.၀၀ US$
+၅၈.၄%
09/09/2026
Thomas Smith
Leerink Partners
Buy
Reiterated
၁၂၈.၀၀ US$
+၆၀.၉%
09/10/2026
Sam Slutsky
LifeSci Capital
Buy
Maintained
၁၁၆.၀၀ US$
+၄၅.၉%
09/08/2026
Yatin Suneja
Guggenheim
Buy
Reiterated
၁၃၀.၀၀ US$
+၆၃.၅%
08/26/2026
Julian Harrison
BTIG
Buy
Reiterated
၁၂၁.၀၀ US$
+၅၂.၁%
08/26/2026
David Hoang
Deutsche Bank
Buy
Maintained
၁၂၇.၀၀ US$
+၅၉.၇%
08/26/2026
Alex Thompson CFA
Stifel Nicolaus
Buy
Maintained
၁၂၃.၀၀ US$
+၅၄.၇%
08/13/2026
Colleen M. Kusy
Robert W. Baird
Buy
Maintained
၁၂၀.၀၀ US$
+၅၀.၉%
08/05/2026
Andy Chen
Wolfe Research
Hold
Downgraded
-
-
07/28/2026
Joseph Catanzaro
Mizuho Securities
Buy
Maintained
၁၂၀.၀၀ US$
+၅၀.၉%
07/13/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
-
-
06/23/2026
Umer Raffat
Evercore ISI
Buy
Maintained
-
-
06/03/2026
Unknown Analyst
Guggenheim
Buy
Reiterated
၁၁၅.၀၀ US$
+၄၄.၆%
05/06/2026
Samantha Semenkow
Citi
Buy
Reiterated
၉၇.၀၀ US$
+၂၂%
05/06/2026
Martin Auster
Raymond James
Buy
Initiated
၈၀.၀၀ US$
+၀.၆%
04/10/2026
Last report
၂၀၂၆ ဩ ၄
Fiscal period
Q2 2026
-၀.၃၆ US$ / -၀.၇၅ US$
+၅၁.၇၈%beat
Revenue / Est. (USD)
- / ၀.၀၀
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
၂၀၂၅ စက်
၂၀၂၅ ဒီ
၂၀၂၆ မတ်
၂၀၂၆ ဇွန်
Revenue
-
-
-
-
Cost of goods sold
၄.၅၂ ကုဋေ
၄.၄၆ ကုဋေ
၆.၀၄ ကုဋေ
၆.၅၅ ကုဋေ
Cost of revenue
၄.၅၂ ကုဋေ
၄.၄၆ ကုဋေ
၆.၀၄ ကုဋေ
၆.၅၅ ကုဋေ
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
၁.၁၆ ကုဋေ
၁.၂၅ ကုဋေ
၁.၅၂ ကုဋေ
၁.၆၁ ကုဋေ
Operating expense
၁.၁၆ ကုဋေ
၁.၂၅ ကုဋေ
၁.၅၂ ကုဋေ
၁.၆၁ ကုဋေ
Total operating expenses
၅.၆၉ ကုဋေ
၅.၇၂ ကုဋေ
၇.၅၆ ကုဋေ
၈.၁၆ ကုဋေ
Operating income
-၅.၆၉ ကုဋေ
-၅.၇၂ ကုဋေ
-၇.၅၆ ကုဋေ
-၈.၁၆ ကုဋေ
Other non operating income
၄.၀၃ ကုဋေ
-၁.၂၅ ကုဋေ
-၃.၀၄ ကုဋေ
-၄.၆၁ သန်း
EBT including unusual items
-၁.၁၂ ကုဋေ
-၆.၂၅ ကုဋေ
-၆.၉၀ ကုဋေ
-၃.၆၂ ကုဋေ
EBT excluding unusual items
-၁.၁၂ ကုဋေ
-၆.၂၅ ကုဋေ
-၉.၉၀ ကုဋေ
-၇.၆၂ ကုဋေ
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-၁.၁၂ ကုဋေ
-၆.၂၅ ကုဋေ
-၆.၉၀ ကုဋေ
-၃.၆၂ ကုဋေ
Net profit margin
-
-
-
-
Earnings per share
-၀.၁၅
-၀.၇၄
-၀.၇၄
-၀.၃၆
Interest and investment income
၅.၃၈ သန်း
၇.၁၄ သန်း
၇.၀၀ သန်း
၁.၀၁ ကုဋေ
Interest expense
-
-
-
-
Net interest expenses
၅.၃၈ သန်း
၇.၁၄ သန်း
၇.၀၀ သန်း
၁.၀၁ ကုဋေ
Depreciation and amortization charges
-
-
-
-
EBITDA
-
-
-
-
Gain or loss from assets sale
-
-
-၃.၀၀ ကုဋေ
-၄.၀၀ ကုဋေ
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google အက်ပ်များ